Gemtuzumab Ozogamicin Treatment Results in Decreased Proliferation and Differentiation of Human Megakaryocytes but Does Not Inhibit Mature Platelet Function
暂无分享,去创建一个
[1] C. Nielsen,et al. Platelet function tests predict bleeding in patients with acute myeloid leukemia and thrombocytopenia , 2019, American journal of hematology.
[2] Frederik Otzen Bagger,et al. BloodSpot: a database of healthy and malignant haematopoiesis updated with purified and single cell mRNA sequencing profiles , 2018, Nucleic Acids Res..
[3] L. Mecklenburg. A Brief Introduction to Antibody–Drug Conjugates for Toxicologic Pathologists , 2018, Toxicologic pathology.
[4] S. Meshinchi,et al. Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia. , 2018, Future oncology.
[5] C. Morisco,et al. Effects of Carvedilol Versus Metoprolol on Platelet Aggregation in Patients With Acute Coronary Syndrome: The PLATE-BLOCK Study. , 2018, The American journal of cardiology.
[6] Jiang Liu,et al. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia , 2018, Clinical Cancer Research.
[7] Jiunn H. Lin,et al. Challenges of Antibody Drug Conjugates in Cancer Therapy: Current Understanding of Mechanisms and Future Strategies , 2018, Current Pharmacology Reports.
[8] D. Stover,et al. Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia , 2017, Molecular Cancer Therapeutics.
[9] J. Kreeger,et al. Liver Microvascular Injury and Thrombocytopenia of Antibody–Calicheamicin Conjugates in Cynomolgus Monkeys—Mechanism and Monitoring , 2016, Clinical Cancer Research.
[10] Heather Donaghy,et al. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates , 2016, mAbs.
[11] R. Dixit,et al. Antibody Drug Conjugates: Nonclinical Safety Considerations , 2015, The AAPS Journal.
[12] R. Abbate,et al. Platelet function tests: a comparative review , 2015, Vascular health and risk management.
[13] M. Sliwkowski,et al. Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1) , 2014, Clinical Cancer Research.
[14] A. Attar. Changes in the Cell Surface Markers During Normal Hematopoiesis: A Guide to Cell Isolation , 2014 .
[15] M. Dittrich,et al. Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests , 2014, Clinical chemistry and laboratory medicine.
[16] M. Linden. Using Platelet Function Testing to Guide Antiplatelet Therapy , 2013 .
[17] R. Scharf. Drugs that Affect Platelet Function , 2012, Seminars in Thrombosis & Hemostasis.
[18] J. Italiano,et al. High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production. , 2012, Blood.
[19] K. Nelander,et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism , 2012, Journal of thrombosis and haemostasis : JTH.
[20] J. Bussel,et al. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia , 2011, Journal of thrombosis and haemostasis : JTH.
[21] A. Ricart. Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin , 2011, Clinical Cancer Research.
[22] D Parent-Massin,et al. Application of human CFU-Mk assay to predict potential thrombocytotoxicity of drugs. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.
[23] T. Lister,et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. , 2005, Blood.
[24] I. Bernstein,et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence , 2005, Cancer.
[25] M. Díaz-Ricart,et al. Uremic platelet dysfunction: past and present. , 2005, Current hematology reports.
[26] A. Leung,et al. Thrombocytopenia after gemtuzumab is reversible by intravenous immunoglobulin , 2005, Leukemia.
[27] M. Berger,et al. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia. , 2002, Clinical lymphoma.
[28] K. Kottke-Marchant,et al. The laboratory diagnosis of platelet disorders. , 2002, Archives of pathology & laboratory medicine.
[29] A. Farrand,et al. Plasma thrombopoietin levels in marrow transplant patients with veno-occlusive disease of the liver , 1998, Bone Marrow Transplantation.
[30] M. Loudovaris,et al. Immunocytochemistry and flow cytometry evaluation of human megakaryocytes in fresh samples and cultures of CD34+ cells. , 1996, Cytometry.
[31] J. Sixma,et al. Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.
[32] Guidelines on platelet function testing. The British Society for Haematology BCSH Haemostasis and Thrombosis Task Force. , 1988, Journal of clinical pathology.
[33] I. Bernstein,et al. Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. , 1987, The Journal of clinical investigation.
[34] R. Branch,et al. A clinical and experimental study of platelet function in chronic renal failure , 1972, Journal of clinical pathology.
[35] H. Horowitz. Uremic toxins and platelet function. , 1970, Archives of internal medicine.
[36] M. Damelin. Innovations for Next-Generation Antibody-Drug Conjugates , 2018, Cancer Drug Discovery and Development.
[37] Hadi Falahatpisheh,et al. Improving the Safety Profile of ADCs , 2018 .
[38] M. Majekova,et al. Carvedilol--a beta-blocker with considerable antiaggregatory effect on human blood platelets. , 2005, Bratislavske lekarske listy.
[39] G. Escolar,et al. Defective platelet adhesion on vessel subendothelium in uremic patients. , 1986, Blood.
[40] P. Miescher,et al. Drug-induced thrombocytopenia , 1980, Clinics in haematology.